Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a...

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic active hepatitis non-A/non-B poses a significant clinical challenge.
• Effective treatment strategies are crucial for improving patient outcomes and survival.

Purpose of the Study:

• To evaluate the efficacy of recombinant interferon-alpha 2b in treating chronic active hepatitis non-A/non-B.
• To assess the impact of interferon therapy on galactose elimination capacity and histological activity.

Main Methods:

• A randomized, controlled multicenter trial involving 88 patients.
• Patients received either 1.5 x 10(6) U of interferon-alpha 2b three times weekly for 1 year or no treatment.
• Outcomes measured included alanine aminotransferase normalization, histological activity index, and galactose elimination capacity.

Main Results:

• Complete response (alanine aminotransferase normalization) was achieved in 47% of the interferon group versus 5% in the control group (P < 0.006).
• Histological activity significantly decreased in responders (P < 0.04), but galactose elimination capacity remained unaffected.
• A sustained response was observed in 22% of patients; no predictors for response or relapse were identified.

Conclusions:

• Low-dose interferon-alpha 2b administered for 1 year is effective in achieving biochemical and histological improvements in chronic active hepatitis non-A/non-B.
• Interferon therapy did not influence galactose elimination capacity, suggesting limited impact on long-term survival.
• The study suggests that a 1-year low-dose interferon regimen is comparable to standard treatment schedules.